Volume 9, Number 6—June 2003
Research
Human Metapneumovirus Infections in Hospitalized Children1
Table 1
Laboratory test | HMPVa |
HRSV |
Influenza A |
Adenovirus |
PIV 2 |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No. tests | Positive (%) | No. tests | Positive (%) | No. tests | Positive (%) | No. tests | Positive (%) | Tests done | Positive (%) | ||
PCR |
208 |
12 (5.8) |
208 |
106 (51.0) |
208 |
45 (21.6) |
NA |
NA |
NA |
NA |
|
Culture |
145 |
2 (1.4 |
145 |
37 (25.5) |
145 |
10 (6.9) |
145 |
6 (4.1) |
145 |
1 (0.7%) |
|
Antigen detection |
NA |
NA |
204 |
94 (46.1) |
172 |
19 (11.0) |
81 |
1 (1.2) |
76 |
1 (1.3%) |
|
Total (+) in at least one test |
12 (5.8%) |
118 (56.7) |
49 (23.6) |
6 (4.1) |
2 (1.3%) |
||||||
Delay between onset of symptoms and NPA, days; mean/median | 6.3/5.0 | 5.2/4.0 | 8.7/5.0 | 6.0/6.5 | 3.0/3.0 |
aHMPV, human metapneumovirus; HRSV, human respiratory syncytial virus; PIV, parainfluenza virus; NPA, nasopharyngeal aspirate; PCR, polymerase chain reaction; NA, not applicable.
1This study was presented in part at the 42nd International Conference on Antimicrobial Agents and Chemotherapy, September 27, 2002, San Diego, California.
Page created: December 22, 2010
Page updated: December 22, 2010
Page reviewed: December 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.